A Pilot Trial of Curcumin Effects on Cognition in Schizophrenia
Launched by YALE UNIVERSITY · Jun 16, 2015
Trial Information
Current as of October 16, 2025
Terminated
Keywords
ClinConnect Summary
This is an 8-week randomized, double-blind, placebo-controlled, parallel, fixed-dose pilot clinical trial of curcumin for the treatment of cognitive impairment in schizophrenia. Cognitive impairment and persistent negative symptoms are the core dimensions of schizophrenia; however current antipsychotic treatment fails to address this issue. Evidence suggests cognitive impairment is not only limited to patients with late-stage schizophrenia. High rates of cognitive impairment in patients with first episode psychosis indicate that cognitive impairment is not solely a consequence of long-term ...
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • 1. 18 - 65 years of age
- • 2. English speaking
- • 3. Diagnostic and Statistical Manual- IV diagnosis of schizophrenia or schizoaffective disorder based on Structured Clinical Interview for Diagnostic and Statistical Manual-IV (SCID)
- • 4. Symptomatic stability confirmed by clinical staff in the 8 weeks prior to the study
- • 5. No changes in antipsychotic medication within the last 8 weeks
- • 6. No change in antipsychotic dose in in last 4 weeks.
- Exclusion criteria are:
- • 1. Unable to provide informed consent
- • 2. Diagnostic and Statistical Manual-IV (DSM-IV) diagnosis of alcohol/substance dependence
- • 3. Recent history of gastrointestinal bleeding or ulceration
- • 4. Recent history of gallstones and/or bile duct obstruction
- • 5. Significant uncontrolled systemic illness (e.g. chronic renal failure, chronic liver disease, poorly controlled diabetes, poorly controlled congestive heart failure, chronic infectious disease, chronic autoimmune disease)
- • 6. Known intolerance to turmeric, curcumin, or curry
- • 7. Pregnancy or breast-feeding
- • 8. Current use of anti-platelet, anti-coagulant, glucocorticoid, immunosuppressants
- • 9. Daily use of non-steroidal anti-inflammatory use.
About Yale University
Yale University, a prestigious Ivy League institution located in New Haven, Connecticut, is renowned for its commitment to advancing medical research and clinical innovation. With a rich history of academic excellence and a robust infrastructure for scientific inquiry, Yale serves as a leading sponsor for clinical trials aimed at improving patient care and developing new therapeutic approaches. The university's multidisciplinary teams of researchers and clinicians collaborate to conduct rigorous and ethical studies, leveraging cutting-edge technologies and methodologies to address critical health challenges. Through its dedication to fostering an environment of inquiry and discovery, Yale University plays a pivotal role in translating research findings into clinical practice, ultimately enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Haven, Connecticut, United States
Patients applied
Trial Officials
Cenk Tek, MD
Principal Investigator
Yale Unversity School of Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials